Clinical

Benjamin Lockshin, MD, FAAD, offers a forward-looking synthesis of how psoriasis care has evolved toward holistic, personalized management—and where advances in oral therapies, biomarker-guided selection, and equitable access will define the next era of treatment.

Real-world data suggest long-acting injectables may help achieve—not just maintain—viral suppression.

Radium-223 retains a role in osteoblastic bone-only disease, while PSMA PET has become indispensable across staging, recurrence detection, and patient selection for radioligand therapy.

Clinicians should consider systemic immunotherapy earlier in CSCC—especially in moderate- to high-risk cases—using a multidisciplinary, patient-centered approach to guide treatment decisions.

TETON-1 data show inhaled treprostinil improves FVC and reduces worsening in IPF, supporting a potential new treatment and combo strategy.

A new study finds that highly lethal cancers receive less research support than lower-risk cancers.

Experts from AMCP discuss the real-world evidence on GLP-1 usage and health care spending.

A new review explains how new therapies and technologies are guiding the treatment of acute myeloid leukemia (AML).

New myeloma therapies—CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina Varshavsky-Yanovsky, MD, PhD.

Experts at AMCP 2026 urged smarter oncology management amid rising costs, complex therapies, and fragmented oversight across plans.

The FDA is encouraging drug sponsors to pursue a new indication for testosterone replacement therapy.

During an afternoon AMCP 2026 session, experts called for integrated clinical and payer care models to combat rising metabolic disease prevalence, costs, and complexity.

The authors updated a diagnosis list to identify low-acuity emergency department visits by veterans and applied it to examine trends and predictors of veterans’ low-acuity utilization.

Steven Kheloussi, PharmD, explains how care coordination and transparent policies can improve MS treatment adherence, streamline access, and balance costs.

A new meta-analysis finds patients who have CLL with “borderline” IGHV status have intermediate outcomes, supporting the need for more precise risk classification.

Patients who were treatment naive or had switched to rituximab saw short-term results of reduced disease activity in multiple sclerosis.

A recent study identified persistent myocardial fibroblast activation in patients with heart failure with reduced ejection fraction, with distinct patterns by etiology.

Experts at AMCP 2026 outlined volatility across the health care landscape that may impact the upcoming midterm elections.

Community response teams can adapt hospital rapid response principles for managed care organizations, targeting rising-risk members to prevent costly clinical deterioration and generate measurable cost savings.

Two posters presented at AMCP 2026 found low dry eye disease (DED) treatment uptake and frequent discontinuation among Medicare patients, whereas comorbid DED did not affect glaucoma adherence.

A clinical pharmacy leader outlines 8 interdependent domains institutions must master to build financially sustainable, patient-accessible CGT programs.

Two posters presented at AMCP 2026 suggest improving GLP-1 adherence and access may enhance outcomes and lower obesity-related costs.

Bone-only, osteoblastic disease and the absence of prior ARPI exposure define the optimal radium-223 candidate, while sequencing relative to lutetium-177 PSMA-617 remains an active area of investigation.

Benjamin Lockshin, MD, FAAD, examines the non-clinical reasons driving real-world treatment discontinuation and explains how clinicians use primary versus secondary loss of efficacy to guide biologic sequencing decisions across IL-23 and IL-17 classes.

Benjamin Lockshin, MD, FAAD, reviews real-world persistence data for tildrakizumab, discussing the interplay of clinical efficacy, insurance coverage, and buy-and-bill reimbursement in driving long-term treatment durability—particularly among Medicare and Medicaid patients.